Clinical trials: Small Airways Disease
Asthma
Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.
- Trial name
- NCT00071552
- Testing
- Qvar, Flovent Diskus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
- Trial name
- NCT07241546
- Testing
- ARO-RAGE
- Where
- 6 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients
This is a crossover Study to investigate the effect of Formoterol versus Salmeterol on small airways physiological parameters in COPD patients.
- Trial name
- Imperial (NCT01344655)
- Testing
- Atimos®, Serevent™
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)
Multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study.
- Trial name
- ATLANTIS (NCT02123667)
- Where
- 26 sites in United States, Brazil and 6 more
- Volunteers
- 872 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
The aim of this study is to evaluate the involvement of small airways in asthma, as determined by bronchial challenges, CT-scanning, and cellular markers of inflammation. Ciclesonide will be inhaled at one dose level once daily.
- Trial name
- NCT00163345
- Testing
- Ciclesonide
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
- Trial name
- NCT02753712
- Testing
- Fluticasone/Formoterol BAI, Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
- Where
- 16 sites in Australia, New Zealand and 3 more
- Volunteers
- 105 people
- Sponsor
- Mundipharma Research Limited
COPD
TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
Efficacy of TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on lung stiffness reduction assessed through area under the reactance curve (AX) using oscillometry in chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04671355
- Testing
- Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg, Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol
The purpose of this study is to demonstrate superiority of Fluticasone/Formoterol (Flutiform®) to Fluticasone/salmeterol based on the small airway function by assessing the Impulse Oscillometic System (IOS) in uncontrolled asthma…
- Trial name
- RECONFFIRM (NCT02491970)
- Testing
- Fluticasone/Formoterol, Fluticasone/Salmeterol
- Volunteers
- 15 people
- Sponsor
- Mundipharma Korea Ltd
Chronic Obstructive Pulmonary Disease
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
This study will evaluate the efficacy and safety data of AZD8871 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03645434
- Testing
- AZD8871, Anoro® Ellipta®
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
COPD
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD patients. Part 2 was an efficacy study in GOLD I-III COPD patients.
- Trial name
- NCT01972776
- Testing
- QBM076
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study in Patients With Asthma
The purpose of the present study is to demonstrate the higher efficacy of Foster® NEXThaler® 100/6 extra fine (two inhalations b.i.d.) versus Seretide® Accuhaler® 250/50 (one inhalation b.i.d.), in terms of pulmonary function…
- Trial name
- NELSON (NCT01570478)
- Testing
- Foster® NEXThaler® 100/6 µg/unit dose, Seretide® Accuhaler® 250/50 µg/actuation
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)
The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction…
- Trial name
- FAIR (NCT01351792)
- Testing
- Foster® 100/6 µg/unit dose, Symbicort® Turbohaler® 200/6 μg/actuation
- Where
- Netherlands
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.